Minneapolis, MN (PRWEB) September 13, 2006
Since the mid-1990s, pharma companies have devised their sales and marketing strategies based on Rx data. However, with the introduction of the AMA's Prescribing Data Restriction Program (PDRP) opt-out program in July 2006, pharma companies need to evaluate the impact of PDRP violation, mediate their PDRP compliance strategies, and revisit their existing Sales Force Effectiveness (SFE) practices. With the introduction of the PDRP, the use of physician Rx data by pharmaceutical companies will never be the same again. The PDRP prohibits access to physician-level Rx data, which directly impacts First Line Managers, Sales Representatives, and anyone else that accesses or distributes physician Rx data.
About the Program
PDRP enrollment began on the AMA’s Web site on July 1, 2006. Pharma companies will get 90 days, from the date of notice received of Physicians ‘opting-out”, to implement the changes in system and technology to comply with the PDRP. A physician may cancel enrollment. All the Pharma company employees in direct interaction with physicians will be blocked from accessing restricted data on PDRP Physicians.
Newly prohibited/blocked data include Rx counts, volume, projected volume, dollars, market share, percent, and any type of change indicators (color coding, up/down arrows, and directional indicators/alerts). Less specific, but more onerous is compliance with the stipulations of the program relative to the use of aggregated/segmented data and the reverse engineering rules. The penalty for violating PDRP compliance can be severe - ranging from loss of ALL access to physician Rx data to strong negative publicity for the company. Violation of reverse engineering rules can also prove adverse for pharma companies. The implications of PDRP violations or inefficient PDRP compliance strategies are too big for pharma companies to ignore.
Pharma companies need to balance the right compliance strategies while maintaining the effectiveness of the sales force. Short and long-term solutions need to be considered to guarantee compliance and ensure a competitive advantage. Pharma companies are in a state of assessing the risks and benefits of being too conservative or too aggressive in implementing PDRP compliance strategies.
Arrowhead Publishers’ new report The Prescribing Data Restriction Program: Critical Assessment and Best Practices estimates the impact of PDRP violations, analyzes the use of Rx data, gauges awareness in the marketplace and benchmarks the best practices towards PDRP compliance.
For more detailed information on this report, click on the report title. For sample pages or ordering information, please call +1 612 929 5203.
# # #